Berenberg Bank Increases Spire Healthcare Group (LON:SPI) Price Target to GBX 300

Spire Healthcare Group (LON:SPI) had its price objective increased by Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a report issued on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Separately, JPMorgan Chase & Co. reaffirmed an overweight rating and issued a GBX 295 ($3.67) price target on shares of Spire Healthcare Group in a research note on Monday, February 26th.

Spire Healthcare Group Stock Performance

Shares of Spire Healthcare Group stock opened at GBX 246 ($3.06) on Wednesday. Spire Healthcare Group has a 52 week low of GBX 204 ($2.54) and a 52 week high of GBX 321.71 ($4.00). The business’s fifty day simple moving average is GBX 237.75 and its 200-day simple moving average is GBX 229.11. The firm has a market cap of £994.16 million, a PE ratio of 3,514.29, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37.

Spire Healthcare Group Increases Dividend

The company also recently announced a dividend, which will be paid on Friday, June 21st. Investors of record on Thursday, May 23rd will be paid a dividend of GBX 2.10 ($0.03) per share. This is a positive change from Spire Healthcare Group’s previous dividend of $0.50. The ex-dividend date is Thursday, May 23rd. This represents a yield of 0.89%. Spire Healthcare Group’s dividend payout ratio is presently 4,285.71%.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.